Navigation Links
AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles

JMR-132 could provide a new therapeutic approach for the treatment of early and metastatic breast cancer

QUEBEC CITY, April 17, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today presented an abstract outlining in vivo data for its growth hormone-releasing hormone (GHRH) antagonist JMR-132 in breast cancer, at the American Association for Cancer Research (AACR) Annual Meeting being held this week at the Los Angeles Convention Center in Los Angeles, California.

Results

The poster #3568 "GHRH-Antagonist in Combination with Docetaxel Chemotherapy induces regression of MX-1 human experimental breast cancers," reviewed preclinical results in breast cancer for JMR-132, the Company's GHRH antagonist which binds to splice variants of the GHRH receptors found on various cancerous tumors. More specifically, the authors reported on the antitumor activity of JMR-132 in MX-1 human experimental, doxorubicin-resistant breast cancers, as well as on the anti-proliferative effect of JMR-132 in combination with docetaxel, which is frequently used for the treatment of early and metastatic breast cancer.

Binding sites were found for GHRH in the MX-1 human breast cancer cell line. The treatment of nude mice bearing MX-1 xenografts with JMR-132 at the dose of 10 (micro)g/day s.c. significantly (p<0.05) inhibited tumor growth, as shown by a 62.9% decrease in tumor volume and 47.8% reduction in tumor weight. Docetaxel at a single dose of 20 mg/kg i.p. significantly reduced tumor volume and weight by 74.1% and 58.6 %, respectively. Combination treatment with JMR-132 and docetaxel led to growth arrest of most MX-1 tumors, evidenced by an inhibition of tumor volume and weight by 97.7 %and 95.6 % respectively (p<0.001).

    Conclusions


    - JMR-132 inhibits doxorubicin resistant in MX-1 human breast cancers

 
   - JMR-132 induces growth arrest or total regression when combined with

      docetaxel chemotherapy

    - JMR-132 could provide a new therapeutic approach to the treatment of

      early and metastatic breast cancer

"We are very pleased and encouraged with these results we have seen to date with JMR-132 which lend further credibility to our very promising oncology platform. By targeting patients suffering from breast cancer with confirmed GHRH receptor status, we believe we may increase our chances of success in future development programs with JMR-132 in this indication. This targeted approach is an additional example of personalized therapy which is becoming more and more the way of the future," said Dr. Jurgen Engel, Executive Vice President, Global R&D and COO of AEterna Zentaris.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global, pure play biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at www.aeternazentaris.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticipates", "intends", "plans", "expects", "estimates", "will," "may", "should", "approximately", and the negative or other variations of those terms or comparable terminology, are forward-looking statements. Such statements reflect management's current views, intentions, strategies and plans and are based on certain assumptions.

Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ ma terially from those in the forward-looking statements. Such risks and uncertainties include, among others, the ability of AEterna Zentaris to implement its business strategies, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of AEterna Zentaris to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

CONTACT: Jenene Thomas, Senior Director, Investor Relations & CorporateCommunications, (418) 655-6420, ; PaulBurroughs, Media Relations (418) 652-8525 ext. 406, jenene.thomas@aeternazentaris.com paul.burroughs@aeternazentaris.com

Ticker Symbol: (Toronto:AEZ.),(NASDAQ-NMS:AEZS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
10. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
11. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... skills and infrastructure. Most providers, however, are unsure how to move forward, given ... to define a path forward tailored to an organization’s specific needs. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially launched its ... by matching users with high quality water pipes within an ideal price range. The ... Inhale was founded by two brothers, Nick and Mike Hunter, who use medical cannabis ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Seema Daulat, a native Texan and University of ... location as of July 13, 2016. , Dr. Daulat earned her Doctorate of Medicine ... regularly volunteered at the Agape Clinic serving Dallas’ underprivileged community. , Following medical school, ...
(Date:6/23/2016)... Los Angeles, CA (PRWEB) , ... June 23, 2016 , ... ... being conducted that may expose a possible link between head and neck cancer in ... individuals participating in the study were evaluated based on whether they had gum disease, ...
(Date:6/23/2016)... ... June 23, 2016 , ... The Mechille Wilson Agency, a Texas-based insurance ... and the surrounding region, is initiating a charity drive to assist a student to ... for a scholarship fund that will be presented to the chosen student to help ...
Breaking Medicine News(10 mins):